A randomized, placebo-controlled clinical trial evaluating the safety and efficacy of the once-weekly DPP-4 inhibitor omarigliptin in patients with type 2 diabetes mellitus inadequately controlled by glimepiride and metformin

Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression. Omarigliptin is a once-weekly dipepti...

Source: BMC Endocrine Disorders - November 6, 2017 Category: Endocrinology Authors: Seung-Hwan Lee, Ira Gantz, Elizabeth Round, Melanie Latham, Edward A. O ’Neill, Paulette Ceesay, Shailaja Suryawanshi, Keith D. Kaufman, Samuel S. Engel and Eseng Lai Tags: Research article Source Type: research